New drug combo aims to shrink rectal tumors before surgery
NCT ID NCT07127497
Summary
This study is testing a new treatment approach for people with locally advanced rectal cancer. Before surgery, patients receive a combination of standard chemotherapy and an immunotherapy drug called sintilimab. The goal is to see if this combination can effectively shrink the tumor and is safe, offering an option for patients who cannot tolerate traditional radiation therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
Conditions
Explore the condition pages connected to this study.